0

Close
 
Upcoming Allied Market Research
2023
Lassa Virus Market

Lassa Virus Market

by Treatment (Ribavirin Tablets, Ribavirin Inhalation Solution, Ribavirin Oral Solution), by Diagnosis (Enzyme-Linked Immunosorbent Serologic Assays (ELISA), Reverse Transcription-Polymerase Chain Reaction (RT-PCR)) and by End User (Hospitals, Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A14035
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Lassa Virus Market

Request Now !

Lassa virus, also known as the Lassa mammarenavirus (LASV), is the arenavirus known to cause Lassa hemorrhagic fever in humans and other primates. Lassa virus requires biosafety level-equivalent containments. It is an endemic in many West African countries such as the Republic of Guinea, Liberia, Nigeria, and Sierra Leona, where the annual number of Lassa viral fever cases is between 300,000 and 500,000, resulting in the annual death of 5,000 infected patients. The spread of the disease is linked to the village of Lassa in Nigeria where a missionary nurse first contracted it in 1969. In humans, the Lassa virus is spread through contact with infected Mastomyl natalensis, the multimammate rat.

COVID-19 Impact Analysis

  • COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020. 
  • Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19. 
  • However, with COVID-19, the supply chain of the raw materials required to manufacture drugs for the Lassa virus has been disrupted in many countries. In addition, the market growth of pharmaceuticals is declining as the manufacturers of drugs have slowed down their production because of the pandemic. This, in turn, is expected to have a significant impact on the Lassa virus market. 

Top Impacting Factors
Rising prevalence of Lassa fever in many developing economies and low-income countries is fuelling the growth of the Lassa virus market. 
Growing population of Mastomys rats all over the world is another factor contributing to the growth of the Lassa virus market. Humans often become infected with the Lassa virus when they come in contact with the feces or urine of infected Mastomys rats. 
Lassa virus is commonly widespread in some areas of Sierra Leone and Liberia; however, international travels from such regions to all corners of the world have increased the chances of the spreading of the virus. This factor is further contributing to the growth of the Lassa virus market.
However, the difficulty to diagnose the Lassa virus based on a patient's clinical presentation and the dearth of skilled healthcare professionals in low-income countries are some of the factors that are impeding the growth of the Lassa virus market. 
Key Market Trends

  • The global Lassa virus market is expected to witness a boost during the forecast period especially in the region of West Africa, owing to the emergence of 100,000 to 300,000 cases of Lassa fever each year.
  • According to the World Health Organization (WHO), around 10–15% of people who have Lassa viral fever belong to the areas of Liberia and Sierra Leone.
  • Key pharmaceutical companies of the Lassa virus market are focused on research and development activities regarding the development of vaccines and diagnostic tests for the Lassa virus.
  • Promising growth in revenue in the Lassa virus market is expected during the forecast period, as various key players of the market are set to launch novel Lassa viral fever treatment products.
  • West Africa dominates the Lassa virus market, due to the presence of large patient pool prone to get infected with the virus and the increasing incidence of the disease in people from all age groups in the Middle East and Africa. 

Key Benefits of the Report

  • This study presents the analytical depiction of the Lassa virus industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the Lassa virus market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
  • Questions Answered in the Lassa Virus Report
  • Which are the leading players active in the Lassa virus market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the Lassa virus in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps in the market?
  • What are the impacts of COVID-19 on the industry?
  • What is the Lassa virus?
  • What are the current and predicted trends of the market?

 Lassa Virus Market Report Highlights

Aspects Details
By Treatment
  • Ribavirin Tablets
  • Ribavirin Inhalation Solution
  • Ribavirin Oral Solution
By Diagnosis
  • Enzyme-Linked Immunosorbent Serologic Assays (ELISA)
  • Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
By End User
  • Hospitals
  • Clinics
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Zydus Pharmaceuticals, F. Hoffmann La Roche AG, Sandoz Inc. (Novartis AG), Teva Pharmaceuticals, Valeant pharmaceuticals international, Three Rivers Pharmaceuticals LLC, Schering-Plough Research Institute
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: LASSA VIRUS MARKET, BY TREATMENT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment

    • 4.2. Ribavirin Tablets

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Ribavirin Inhalation Solution

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Ribavirin Oral Solution

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: LASSA VIRUS MARKET, BY DIAGNOSIS

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Diagnosis

    • 5.2. Enzyme-Linked Immunosorbent Serologic Assays (ELISA)

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: LASSA VIRUS MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Clinics

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: LASSA VIRUS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Treatment

      • 7.2.3. Market Size and Forecast, By Diagnosis

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Lassa Virus Market

        • 7.2.6.1. Market Size and Forecast, By Treatment
        • 7.2.6.2. Market Size and Forecast, By Diagnosis
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Lassa Virus Market

        • 7.2.7.1. Market Size and Forecast, By Treatment
        • 7.2.7.2. Market Size and Forecast, By Diagnosis
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Lassa Virus Market

        • 7.2.8.1. Market Size and Forecast, By Treatment
        • 7.2.8.2. Market Size and Forecast, By Diagnosis
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Treatment

      • 7.3.3. Market Size and Forecast, By Diagnosis

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Lassa Virus Market

        • 7.3.6.1. Market Size and Forecast, By Treatment
        • 7.3.6.2. Market Size and Forecast, By Diagnosis
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Lassa Virus Market

        • 7.3.7.1. Market Size and Forecast, By Treatment
        • 7.3.7.2. Market Size and Forecast, By Diagnosis
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Lassa Virus Market

        • 7.3.8.1. Market Size and Forecast, By Treatment
        • 7.3.8.2. Market Size and Forecast, By Diagnosis
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Lassa Virus Market

        • 7.3.9.1. Market Size and Forecast, By Treatment
        • 7.3.9.2. Market Size and Forecast, By Diagnosis
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Lassa Virus Market

        • 7.3.10.1. Market Size and Forecast, By Treatment
        • 7.3.10.2. Market Size and Forecast, By Diagnosis
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Lassa Virus Market

        • 7.3.11.1. Market Size and Forecast, By Treatment
        • 7.3.11.2. Market Size and Forecast, By Diagnosis
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Lassa Virus Market

        • 7.3.12.1. Market Size and Forecast, By Treatment
        • 7.3.12.2. Market Size and Forecast, By Diagnosis
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Treatment

      • 7.4.3. Market Size and Forecast, By Diagnosis

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Lassa Virus Market

        • 7.4.6.1. Market Size and Forecast, By Treatment
        • 7.4.6.2. Market Size and Forecast, By Diagnosis
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Lassa Virus Market

        • 7.4.7.1. Market Size and Forecast, By Treatment
        • 7.4.7.2. Market Size and Forecast, By Diagnosis
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Lassa Virus Market

        • 7.4.8.1. Market Size and Forecast, By Treatment
        • 7.4.8.2. Market Size and Forecast, By Diagnosis
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Lassa Virus Market

        • 7.4.9.1. Market Size and Forecast, By Treatment
        • 7.4.9.2. Market Size and Forecast, By Diagnosis
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Lassa Virus Market

        • 7.4.10.1. Market Size and Forecast, By Treatment
        • 7.4.10.2. Market Size and Forecast, By Diagnosis
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Lassa Virus Market

        • 7.4.11.1. Market Size and Forecast, By Treatment
        • 7.4.11.2. Market Size and Forecast, By Diagnosis
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Lassa Virus Market

        • 7.4.12.1. Market Size and Forecast, By Treatment
        • 7.4.12.2. Market Size and Forecast, By Diagnosis
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Lassa Virus Market

        • 7.4.13.1. Market Size and Forecast, By Treatment
        • 7.4.13.2. Market Size and Forecast, By Diagnosis
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Lassa Virus Market

        • 7.4.14.1. Market Size and Forecast, By Treatment
        • 7.4.14.2. Market Size and Forecast, By Diagnosis
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Treatment

      • 7.5.3. Market Size and Forecast, By Diagnosis

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Lassa Virus Market

        • 7.5.6.1. Market Size and Forecast, By Treatment
        • 7.5.6.2. Market Size and Forecast, By Diagnosis
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Lassa Virus Market

        • 7.5.7.1. Market Size and Forecast, By Treatment
        • 7.5.7.2. Market Size and Forecast, By Diagnosis
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Lassa Virus Market

        • 7.5.8.1. Market Size and Forecast, By Treatment
        • 7.5.8.2. Market Size and Forecast, By Diagnosis
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Lassa Virus Market

        • 7.5.9.1. Market Size and Forecast, By Treatment
        • 7.5.9.2. Market Size and Forecast, By Diagnosis
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Lassa Virus Market

        • 7.5.10.1. Market Size and Forecast, By Treatment
        • 7.5.10.2. Market Size and Forecast, By Diagnosis
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Lassa Virus Market

        • 7.5.11.1. Market Size and Forecast, By Treatment
        • 7.5.11.2. Market Size and Forecast, By Diagnosis
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Zydus Pharmaceuticals

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Valeant Pharmaceuticals International

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. F. Hoffmann La Roche AG

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Sandoz Inc. (Novartis AG)

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Teva Pharmaceuticals

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Three Rivers Pharmaceuticals LLC

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Schering-Plough Research Institute

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL LASSA VIRUS MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL LASSA VIRUS MARKET FOR RIBAVIRIN TABLETS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL LASSA VIRUS MARKET FOR RIBAVIRIN INHALATION SOLUTION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL LASSA VIRUS MARKET FOR RIBAVIRIN ORAL SOLUTION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL LASSA VIRUS MARKET, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL LASSA VIRUS MARKET FOR ENZYME-LINKED IMMUNOSORBENT SEROLOGIC ASSAYS (ELISA), BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL LASSA VIRUS MARKET FOR REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR), BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL LASSA VIRUS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL LASSA VIRUS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL LASSA VIRUS MARKET FOR CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL LASSA VIRUS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL LASSA VIRUS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA LASSA VIRUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 17. U.S. LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 18. U.S. LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 19. U.S. LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. CANADA LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 21. CANADA LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 22. CANADA LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE LASSA VIRUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. FRANCE LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 31. FRANCE LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 32. FRANCE LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. ITALY LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 37. ITALY LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 38. ITALY LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. SPAIN LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 40. SPAIN LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. UK LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 43. UK LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 44. UK LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. RUSSIA LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 46. RUSSIA LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 47. RUSSIA LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC LASSA VIRUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. CHINA LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 56. CHINA LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 57. CHINA LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 60. JAPAN LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. INDIA LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 62. INDIA LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 63. INDIA LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. AUSTRALIA LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 68. AUSTRALIA LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 69. AUSTRALIA LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. THAILAND LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 71. THAILAND LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 72. THAILAND LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 73. MALAYSIA LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 74. MALAYSIA LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 75. MALAYSIA LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 76. INDONESIA LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 77. INDONESIA LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 78. INDONESIA LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 79. REST OF ASIA PACIFIC LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 82. LAMEA LASSA VIRUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 83. LAMEA LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 84. LAMEA LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 85. LAMEA LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. BRAZIL LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 87. BRAZIL LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 88. BRAZIL LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH AFRICA LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH AFRICA LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH AFRICA LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 92. SAUDI ARABIA LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 93. SAUDI ARABIA LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 94. SAUDI ARABIA LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 95. UAE LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 96. UAE LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 97. UAE LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 98. ARGENTINA LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 99. ARGENTINA LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 100. ARGENTINA LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 101. REST OF LAMEA LASSA VIRUS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 102. REST OF LAMEA LASSA VIRUS, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 103. REST OF LAMEA LASSA VIRUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 104. ZYDUS PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 105. ZYDUS PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 106. ZYDUS PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 107. ZYDUS PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 108. ZYDUS PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. VALEANT PHARMACEUTICALS INTERNATIONAL: KEY EXECUTIVES
  • TABLE 110. VALEANT PHARMACEUTICALS INTERNATIONAL: COMPANY SNAPSHOT
  • TABLE 111. VALEANT PHARMACEUTICALS INTERNATIONAL: OPERATING SEGMENTS
  • TABLE 112. VALEANT PHARMACEUTICALS INTERNATIONAL: PRODUCT PORTFOLIO
  • TABLE 113. VALEANT PHARMACEUTICALS INTERNATIONAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. F. HOFFMANN LA ROCHE AG: KEY EXECUTIVES
  • TABLE 115. F. HOFFMANN LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 116. F. HOFFMANN LA ROCHE AG: OPERATING SEGMENTS
  • TABLE 117. F. HOFFMANN LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 118. F. HOFFMANN LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. SANDOZ INC. (NOVARTIS AG): KEY EXECUTIVES
  • TABLE 120. SANDOZ INC. (NOVARTIS AG): COMPANY SNAPSHOT
  • TABLE 121. SANDOZ INC. (NOVARTIS AG): OPERATING SEGMENTS
  • TABLE 122. SANDOZ INC. (NOVARTIS AG): PRODUCT PORTFOLIO
  • TABLE 123. SANDOZ INC. (NOVARTIS AG): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 124. TEVA PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 125. TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 126. TEVA PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 127. TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 128. TEVA PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 129. THREE RIVERS PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 130. THREE RIVERS PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 131. THREE RIVERS PHARMACEUTICALS LLC: OPERATING SEGMENTS
  • TABLE 132. THREE RIVERS PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 133. THREE RIVERS PHARMACEUTICALS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 134. SCHERING-PLOUGH RESEARCH INSTITUTE: KEY EXECUTIVES
  • TABLE 135. SCHERING-PLOUGH RESEARCH INSTITUTE: COMPANY SNAPSHOT
  • TABLE 136. SCHERING-PLOUGH RESEARCH INSTITUTE: OPERATING SEGMENTS
  • TABLE 137. SCHERING-PLOUGH RESEARCH INSTITUTE: PRODUCT PORTFOLIO
  • TABLE 138. SCHERING-PLOUGH RESEARCH INSTITUTE: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL LASSA VIRUS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL LASSA VIRUS MARKET
  • FIGURE 3. SEGMENTATION LASSA VIRUS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN LASSA VIRUS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALLASSA VIRUS MARKET
  • FIGURE 11. LASSA VIRUS MARKET SEGMENTATION, BY BY TREATMENT
  • FIGURE 12. LASSA VIRUS MARKET FOR RIBAVIRIN TABLETS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. LASSA VIRUS MARKET FOR RIBAVIRIN INHALATION SOLUTION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. LASSA VIRUS MARKET FOR RIBAVIRIN ORAL SOLUTION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. LASSA VIRUS MARKET SEGMENTATION, BY BY DIAGNOSIS
  • FIGURE 16. LASSA VIRUS MARKET FOR ENZYME-LINKED IMMUNOSORBENT SEROLOGIC ASSAYS (ELISA), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. LASSA VIRUS MARKET FOR REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. LASSA VIRUS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 19. LASSA VIRUS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. LASSA VIRUS MARKET FOR CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. LASSA VIRUS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 26. COMPETITIVE DASHBOARD
  • FIGURE 27. COMPETITIVE HEATMAP: LASSA VIRUS MARKET
  • FIGURE 28. Top player positioning, 2022
  • FIGURE 29. ZYDUS PHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 30. ZYDUS PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 31. ZYDUS PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 32. VALEANT PHARMACEUTICALS INTERNATIONAL: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. VALEANT PHARMACEUTICALS INTERNATIONAL: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. VALEANT PHARMACEUTICALS INTERNATIONAL: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. F. HOFFMANN LA ROCHE AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. F. HOFFMANN LA ROCHE AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. F. HOFFMANN LA ROCHE AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. SANDOZ INC. (NOVARTIS AG): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. SANDOZ INC. (NOVARTIS AG): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. SANDOZ INC. (NOVARTIS AG): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. TEVA PHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. TEVA PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. TEVA PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. THREE RIVERS PHARMACEUTICALS LLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. THREE RIVERS PHARMACEUTICALS LLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. THREE RIVERS PHARMACEUTICALS LLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. SCHERING-PLOUGH RESEARCH INSTITUTE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. SCHERING-PLOUGH RESEARCH INSTITUTE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. SCHERING-PLOUGH RESEARCH INSTITUTE: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Lassa Virus Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers